Davis Polk advised the underwriters in connection with a $75 million public offering of common stock by RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is listed on the Nasdaq Global Market under the symbol “RAPT.”

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.

The Davis Polk corporate team included partner Emily Roberts and associates Scott A. Blumenkranz and Jonathan Bye. Partner Rachel D. Kleinberg and associate Adam R. Brownstone provided tax advice. Partner David R. Bauer and associates Mikaela Dealissia and Jennifer Leather provided intellectual property advice. Counsel Gregory D. Hughes provided executive compensation advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post